Progestogens in hormonal replacement therapy: new molecules, risks, and benefits

Area of Science:

• Endocrinology
• Pharmacology
• Women's Health

Background:

• Progestogens are crucial for endometrial protection in hormone replacement therapy (HRT).
• However, concerns exist regarding the risks and side effects associated with different progestogen types.
• Progestogens exhibit varying pharmacological properties, influencing their safety and efficacy profiles.

Purpose of the Study:

• To review the diverse effects of progestogens used in HRT.
• To differentiate side effects based on progestogen chemical structure and receptor binding.
• To evaluate the impact of progestogen selection on cardiovascular and breast health outcomes.

Main Methods:

• Literature review of studies on progestogen pharmacology and clinical outcomes in HRT.
• Analysis of progestogen binding affinities to androgen, mineralocorticoid, and glucocorticoid receptors.
• Examination of epidemiological data on cardiovascular morbidity, mortality, and breast cancer risk associated with HRT.

Main Results:

• Progestogens differ significantly; natural progesterone and 19-norprogesterones lack androgenic effects.
• Drospirenone and dienogest are non-androgenic but may have antiandrogenic or mineralocorticoid activity.
• Epidemiological data show no increased cardiovascular risk with HRT, but androgenic progestogens may be detrimental in women with existing heart disease.
• Progestogens generally show antiproliferative effects on breast cells, with no significant increase in breast cancer risk compared to estrogen-only therapy.

Conclusions:

• The choice of progestogen in HRT is critical for managing side effects and optimizing outcomes.
• Selecting progestogens devoid of estrogenic, androgenic, or glucocorticoid activity may enhance HRT safety and tolerability.
• Further research into specific progestogen profiles can guide personalized HRT prescriptions.